Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648931 | 0.98 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL20817034 | 0.81 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL221473 | 0.81 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28158071 | 0.79 | CYP1A2 (0.39) | CYP1A2CYP2D6 | |
| SCHEMBL28862327 | 0.77 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL7378891 | 0.77 | — | — | |
| Water SCHEMBL27520041 | 0.77 | CYP1A2 (0.41) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL27481863 | 0.76 | CYP1A2 (0.37) | CYP1A2CYP2D6 | |
| Methylene Chloride SCHEMBL28221251 | 0.76 | CYP1A2 (0.37) | CYP1A2CYP2D6 | |
| SCHEMBL6952064 | 0.74 | NAAA (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109970741-A | Amino pyridazine ketone compound as kinases inhibitor | 江苏恒瑞医药股份有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-105163733-B | Furan ketone compound as kinase inhibitor | 永恒生物科技公司 | 2019-05-31 | — | — | CN | disclosed |
| CN-106573001-B | Aminopyridazinone compounds as protein kinase inhibitors | 江苏恒瑞医药股份有限公司 | 2019-01-29 | — | — | CN | disclosed |
| CN-108290845-A | pyrimidine compounds | 大日本住友制药株式会社 | 2018-07-17 | — | — | CN | disclosed |
| CN-108200760-A | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | 英安塔制药有限公司 | 2018-06-22 | — | — | CN | disclosed |
| CN-107921288-A | The targeting conjugate of KSP inhibitor | 拜耳医药股份有限公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107427527-A | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | 英安塔制药有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107249594-A | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | 英安塔制药有限公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-107231795-A | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof | 英安塔制药有限公司 | 2017-10-03 | — | — | CN | disclosed |
| CN-107106575-A | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | 英安塔制药有限公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-106573001-A | Aminopyridazinone compounds as protein kinase inhibitors | 永恒生物科技公司 | 2017-04-19 | — | — | CN | disclosed |
| US-7485732-B2 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK & CO., INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20060293299-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2006-12-28 | — | — | US | disclosed |
| EP-1515958-A2 | PROCESS FOR THE SYNTHESIS OF MOSAPRIDE | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2005-03-23 | — | — | EP | disclosed |
| CN-1478078-A | Nitrogen-containing aromatic ring derivatives | ������������ʽ���� | 2004-02-25 | — | — | CN | disclosed |
| WO-2003106440-A2 | PROCESS FOR THE SYNTHESIS OF A BENZAMIDE DERIVATIVE | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-12-24 | — | — | WO | disclosed |
| EP-0393457-B1 | Proteinase inhibitor | SUNTORY LTD (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0413709-A4 | FATTY AMINO ACIDS, AND HOMO- AND HETERO-OLIGOMERS AND CONJUGATES THEREOF | GIBBONS WILLIAM ANTHONY (GB) | 1991-12-27 | — | — | EP | disclosed |
| EP-0413709-A1 | FATTY AMINO ACIDS, AND HOMO- AND HETERO-OLIGOMERS AND CONJUGATES THEREOF | THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON (GB) | 1991-02-27 | — | — | EP | disclosed |
| WO-1989010348-A1 | FATTY AMINO ACIDS, AND HOMO- AND HETERO-OLIGOMERS AND CONJUGATES THEREOF | SYNPHARM LTD (GB) | 1989-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293299-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | CNR1, CNR2, MAG | CYP1A2 539/4885CYP2D6 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.